Biopool International, based in Ventura, has received Food and Drug Administration approval to market the company's new Chromolize PAI-1 Assay Kit, which measures a key protein in blood.
The targeted protein, plasminogen activator inhibitor-1, regulates the body's ability to break down blood clots.
An inability to break clots down is associated with the incidence of coronary heart disease, Biopool officials said.
The Chromolize PAI-1 kit is Biopool's third-generation test kit for PAI-1 activity. The first kit was introduced in 1992.
This represents Biopool's eighth FDA approval this year, company officials said.
Founded in 1987, Biopool International develops and manufactures test kits to assess and diagnose blood disorders.